James Lomas

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Topics

Top Venues

Health economics

PharmacoEconomics

Health policy and planning

This page only lists publications with an associated author ORCID identifier.

Publications

Bethan Woods, James Lomas, Mark Sculpher, Helen Weatherly, Karl Claxton
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health economics 33 (4) (2024)
Bethan Woods, James Lomas, Mark Sculpher, Helen Weatherly, Karl Claxton
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health economics (2024)
Bethan Woods, James Lomas, Mark Sculpher, Helen Weatherly, Karl Claxton
Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health economics 33 (4) (2024)
Callum Brindley, James Lomas, Luigi Siciliani
The effect of hospital spending on waiting times. Health economics (2023)
Victoria Charlton, Michael J DiStefano, Polly Mitchell, Liz Morrell, Leah Zoe Gibson Rand, Gabriele Badano, Rachel Mairi Baker, Michael Calnan, Kalipso Chalkidou, Anthony J Culyer, Daniel Howdon, Dyfrig A Hughes, James Lomas, Catherine Max, Christopher McCabe, James F O'Mahony, Mike Paulden, Zack Pemberton-Whiteley, Annette Rid, Paul A Scuffham, Mark J Sculpher, Koonal Kirit Shah, Albert Weale, Gry Wester
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment. Health economics, policy, and law (2023)
Ahmed Hamdan Al-Jedai, James Lomas, Hajer Yousef Almudaiheem, Yazed Sulaiman H Al-Ruthia, Shabab Alghamdi, Nancy Awad, Ahlam Alghamdi, Mohammad A Alowairdhi, Hana Alabdulkarim, Majid Almadi, Reem F Bunyan, Jessica Ochalek
Informing a cost-effectiveness threshold for Saudi Arabia. Journal of medical economics 26 (1) (2023)
Francesco Longo, Karl Claxton, James Lomas, Stephen Martin
Is extending eligibility for adult social care better than investing more in existing users in England? A cross-sectional evidence for multiple financial years. BMJ open 13 (9) (2023)
James Lomas, Karl Claxton, Jessica Ochalek
Accounting for Country- and Time-Specific Values in the Economic Evaluation of Health-Related Projects Relevant to low- and Middle-Income Countries. Health policy and planning (2021)
Stephen Martin, Francesco Longo, James Lomas, Karl Claxton
Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. BMJ open 11 (10) (2021)
Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, James Lomas, Henry Cutler, Chunlin Jin
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. PharmacoEconomics 38 (12) (2021)
Jessica Ochalek, Kaja M Abbas, Karl Claxton, Mark Jit, James Lomas
Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ global health 5 (10) (2021)
Matthew Franklin, James Lomas, Gerry Richardson
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations. PharmacoEconomics 38 (7) (2021)
James Lomas, Jessica Ochalek, Rita Faria
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. Applied health economics and health policy (2021)
Francesco Longo, Karl Claxton, James Lomas, Stephen Martin
Does public long-term care expenditure improve care-related quality of life of service users in England? Health economics 30 (10) (2021)
Matthew Franklin, James Lomas, Simon M Walker, Tracey Young
An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. PharmacoEconomics 37 (5) (2020)
Stephen Martin, James Lomas, Karl Claxton
Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BMJ open 10 (10) (2020)
Karl Claxton, James Lomas, Stephen Martin
The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health economics 27 (6) (2018)